OPALE, the Organization
for Partnerships in Leukemia
The OPALE Carnot institute is a healthcare industry’s preferred partner for the research and development of innovative solutions aimed at diagnosis, treatment and follow-up of patients in the field of leukemia and related diseases, the deadliest blood cancer and first child cancer.
An unparalleled partnership offer
The OPALE Carnot Institute gives healthcare companies unique access to the expertise of an internationally unparalleled consortium in the field of leukemia and related diseases. Our aim is to prolong or save the lives of more patients by accelerating therapeutic and diagnostic innovation across the entire research and development value chain.
Explore our offer
Carnot, a label of excellence
Granted by the French Ministry of Higher Education, Research and Innovation, the Carnot label is prestigious and highly selective.
Being labelled Carnot is a guarantee of scientific and operational excellence in R&D collaborations for our industrial partners.
The Carnot institutes follow their namesake Charter to guarantee top-tier collaborative research, effectively driving industrial advancements while ensuring ongoing scientific revitalization within the Carnot community.
"The OPALE Carnot Institute addresses many of the needs of manufacturers in the leukemia market, thanks to the specialization and depth of its R&D offering, accessible through a one-stop shop."
Medical Director of a pharmaceutical company
Member of OPALE's Strategic Advisory Committee
"Accelerating the emergence of innovative solutions for the diagnosis, treatment, and follow-up of patients in the field of leukemia and related diseases"
Pr Hervé Dombret
OPALE's Chairman
News
Le séminaire d'équipe de l'Institut Carnot OPALE, est lancé, cette année à Marseille !
May 5, 2025, 10:13 a.m.
À Marseille, le séminaire 2025 de l’Institut Carnot OPALE réunit chercheurs et partenaires autour d’un objectif : renforcer les collaborations pour innover dans les leucémies et maladies apparentées..
> Read moreIn vivo CAR-T : vers une nouvelle génération de thérapies cellulaires
May 5, 2025, 10:09 a.m.
Moins complexes, plus accessibles : les CAR in vivo pourraient transformer la prise en charge des leucémies. L’Institut Carnot OPALE participe à leur essor via le consortium UNITC, présenté lors d’une session clé à SFH 2025.
> Read morePersonnaliser les traitements en leucémie : les groupes coopérateurs au cœur des avancées
May 5, 2025, 10:05 a.m.
Personnaliser les traitements contre les leucémies devient une réalité grâce aux groupes coopérateurs du consortium OPALE. À la SFH 2025, leurs études dessinent les protocoles de demain — plus ciblés, moins toxiques, et mieux adaptés aux patients.
> Read more